Avanos Medical (AVNS) Projected to Post Earnings on Tuesday

Avanos Medical (NYSE:AVNS - Get Free Report) will likely be releasing its Q2 2025 earnings data before the market opens on Tuesday, August 5th. Analysts expect Avanos Medical to post earnings of $0.18 per share and revenue of $165.50 million for the quarter. Avanos Medical has set its FY 2025 guidance at 0.750-0.950 EPS.

Avanos Medical (NYSE:AVNS - Get Free Report) last announced its earnings results on Tuesday, May 6th. The company reported $0.26 EPS for the quarter, topping the consensus estimate of $0.19 by $0.07. Avanos Medical had a negative net margin of 55.80% and a positive return on equity of 6.26%. The company had revenue of $167.50 million during the quarter, compared to analysts' expectations of $161.75 million. During the same period last year, the company posted $0.22 earnings per share. The business's revenue for the quarter was up .8% on a year-over-year basis. On average, analysts expect Avanos Medical to post $1 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Avanos Medical Trading Up 1.1%

Shares of AVNS traded up $0.13 during midday trading on Friday, hitting $12.01. The stock had a trading volume of 397,298 shares, compared to its average volume of 420,827. Avanos Medical has a fifty-two week low of $11.21 and a fifty-two week high of $25.36. The business has a 50-day simple moving average of $12.23 and a two-hundred day simple moving average of $13.74. The firm has a market cap of $555.25 million, a P/E ratio of -1.43 and a beta of 1.12. The company has a current ratio of 2.57, a quick ratio of 1.56 and a debt-to-equity ratio of 0.12.

Institutional Trading of Avanos Medical

A number of hedge funds have recently made changes to their positions in the stock. Intech Investment Management LLC lifted its position in shares of Avanos Medical by 154.3% in the first quarter. Intech Investment Management LLC now owns 124,061 shares of the company's stock worth $1,778,000 after purchasing an additional 75,279 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in Avanos Medical by 17.1% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 140,810 shares of the company's stock valued at $2,018,000 after acquiring an additional 20,541 shares in the last quarter. Empowered Funds LLC raised its position in Avanos Medical by 5.4% during the first quarter. Empowered Funds LLC now owns 162,182 shares of the company's stock valued at $2,324,000 after acquiring an additional 8,348 shares in the last quarter. Millennium Management LLC raised its position in Avanos Medical by 508.3% during the first quarter. Millennium Management LLC now owns 547,740 shares of the company's stock valued at $7,849,000 after acquiring an additional 457,703 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Avanos Medical by 4.3% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 26,955 shares of the company's stock valued at $386,000 after acquiring an additional 1,121 shares in the last quarter. 95.17% of the stock is owned by hedge funds and other institutional investors.

Avanos Medical Company Profile

Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.